|
|
Article: Spherix Signs Agreement to Conduct Phase 3 Clinical Trial and Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes.
- Article from:
- M2 Presswire
- Article date:
- May 24, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-24 May 2006-US Equity Network: Spherix Signs Agreement to Conduct Phase 3 Clinical Trial and Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:24052005
City of Industry, CA - Diabetes research update provided by U.S. Equity News. Spherix Incorporated (Nasdaq: SPEX) has signed an agreement with GleneaglesCRC, a major clinical research and drug development company based in Singapore, to conduct its phase 3 clinical trial on the use of Naturlose as a treatment for type 2 diabetes. Gleneagles has a record for participating in U.S. FDA approved clinical trials. Curis, Inc. (NASDAQ: CRIS), a ...